



Docket No. CRD-0929

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gerard H. Llanos, et al.

Serial No. : 09/887,464
Filed : June 22, 2001

Art Unit: 3743
Examiner: Nguyen, C. T.

For : Local Drug Delivery Devices And Methods For
Maintaining The Drug Coatings Thereon

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September 13, 2006
(Date of Deposit)

Carl J. Evens
(Name of applicant, assignee, or Registered Representative)

/Carl J. Evens/

(Signature)

September 13, 2006

(Date of Signature)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☒ There are no listed references which are not in the English language.

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/CRD-0929/CJE. This form is
submitted in triplicate.

Respectfully submitted,

/Carl J. Evens/

Carl J. Evens
Reg. No. 33,874
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518
DATED: September 13, 2006



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
	Confirmation No. 8413	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	2002/111590 A1	08/15/02	Davila et al.	604	265
	2	2004/0102758 A1	05/27/04	Davila et al.	604	500
	3	3,585,707	06/22/71	Stevens	29	426.2
	4	3,929,992	12/30/75	Seghal et al.	424	122
	5	3,959,078	05/25/76	Guire	530	350
	6	4,366,819	01/04/83	Kaster	606	153
	7	4,368,736	01/18/83	Kaster	606	153
	8	4,613,665	09/23/86	Larm	536	20
	9	4,624,257	11/25/86	Berggren et al.	606	153
	10	4,722,906	02/02/88	Guire	436	501
	11	4,733,665	03/29/88	Palmaz	606	108
	12	4,739,665	04/26/88	Nordvall	73	862.08
	13	4,810,784	03/07/89	Larm	536	20
	14	4,917,090	04/17/90	Berggren et al.	606	153
	15	4,917,091	04/17/90	Berggren et al.	606	153
	16	5,045,072	09/03/91	Castillo et al.	604	529
	17	5,049,403	09/17/91	Larm et al.	427	2.1
	18	5,229,172	07/20/93	Cahalan et al.	427	536
	19	5,254,107	10/19/93	Soltesz	604	525
	20	5,308,641	05/03/94	Cahalan et al.	427	2.1

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
	Confirmation No. 8413	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	21	5,350,800	09/27/94	Verhoeven et al.	525	54.2
	22	5,415,938	05/16/95	Cahalan et al.	428	409
	23	5,883,651	03/16/99	Thiel et al.	347	71
	24	5,924,997	07/20/99	Campbell	600	549
	25	6,099,562	08/08/00	Ding et al.	623	1.46
	26	6,245,026	06/12/01	Campbell et al.	600	549
	27	6,425,898	07/30/02	Wilson et al.	606	108
	28	6,713,119	03/30/04	Hossainy et al.	427	2.25

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
	Confirmation No. 8413	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	29	98/33443 A1	08/06/98	WO		
	30	02/26139 A1	04/04/02	WO		
	31	03/000308 A1	01/03/03	WO		

EXAMINER	DATE CONSIDERED
-----------------	------------------------




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
Confirmation No. 8413		

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

32	Ajroldi, G. et al., "Fluoroelastomers-dependence of relaxation phenomena on composition," POLYMER, 1989, 30, 2180-2187
33	Berk, B. C. et al., "Heparins and Glucocorticoids Inhibit Restenosis," J. Am. Coll. Cardiol., 1991, 17, 111B-117B
34	Brehm, B. R. et al., "Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells," J Cardiovasc Pharmacol, Nov. 2000, 36(5 Suppl 1), S401-S403
35	Campbell, G. R. and Campbell, J. H., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture," In: <i>Vascular Smooth Muscle in Culture</i> , Vol. 1, Ch. 4, Boca Raton, FL: CRC, 1987, pp. 39-55
36	Campbell, G. R., et al., "Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis," Exp. Mol. Pathol., April 1985, 42(2), 139-162
37	Carrera, C. J. et al., "Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy," J. Clin. Invest, 1990 86(5), 1480-1488
38	Carson, D. A. et al., "DNA strand breaks, NAD metabolism, and programmed cell death," Exp Cell Res, 1986 Jun, 164(2), 273-281
39	Carson, D. A. et al., "Genetic analysis of deoxyadenosine toxicity in dividing human lymphoblasts," Adv Exp Med Biol, 1986, 195 Pt B, 207-211
40	Carson, D. A. et al., "Lymphocyte dysfunction after DNA damage by toxic oxygen species. A model of immunodeficiency," J Exp Med., 1986 Mar 1; 163(3), 746-751
41	Carson, D. A. et al., "Metabolism to methionine and growth stimulation by 5'-methylthioadenosine and 5'-methylthioinosine in mammalian cells," Biochem Biophys Res Commun, 1983 Apr 29, 112(2), 391-397
42	Carson, D. A. et al., "Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes," Blood, 1983 Oct, 62(4), 737-743
43	Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent," J. Clin. Invest., 1995, 96, 2260-2268
44	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin," Lab. Invest., 1985, 52(6), 611-616

EXAMINER

DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CRD-0929	Application No. 09/887,464
		Applicant Gerard H. Llanos, et al.	
		Filing Date June 22, 2001	Group 3743
		Confirmation No. 8413	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	45	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," Circ. Res., 1986, 58(6), 839-845	
	46	Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," Circ Res. 1985, 56(1), 139-145	
	47	Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," Nature, 1977, 265(5595), 625-626	
	48	Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," J. Vasc. Surg., 1992, 15, 510-518	
	49	Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," Supplement to Circulation. Abstracts From the 62 nd Scientific Sessions., 1989, 80(4), Abstract No. 0263	
	50	Edelman, E. R. et al., "Pathobiologic responses to stenting," Am J. Cardiol. 1998, 81(7A), 4E-6E	
	51	Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," Circ. Res., 1997, 80, 542-550	
	52	Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," Science, 1991, 253, 1129-1132	
	53	Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," N. Eng. J. Med., 1994 Aug 25, 331(8), 496-501	
	54	Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," Coron Artery Dis. 1993 Mar, 4(3), 232-242	
	55	Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," Eur. J. Pharmacol., 1996, 318, 327-332	
	56	Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," Circ. Res., 1980, 46, 625-634	

EXAMINER

DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CRD-0929	Application No. 09/887,464
		Applicant Gerard H. Llanos, et al.	
		Filing Date June 22, 2001	Group 3743
		Confirmation No. 8413	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	57	Hanson, S. R. et al., "Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone," Proc. Natl. Acad. Sci. USA, 1988, 85, 3184-3188	
	58	Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," Circ., 1991, 84, 1266-1272	
	59	Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," Proc. Natl., Acad. Sci., 1988, 85, 2303-2306	
	60	Lang, R. J. et al., "Effects of 2,3-butanedione monoxime on whole-cell Ca^{2+} channel currents in single cells of the guinea-pig taenia caeci," J Physiol. 1991 Feb, 433, 1-24	
	61	Lang, R. J. et al., "Effects of okadaic acid and ATP gamma S on cell length and Ca^{2+} -channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci," Br. J. Pharmacol., 1991 Oct, 104(2), 331-336	
	62	Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 1089-1093	
	63	Lundergan, C. F. et al., "Peptide Inhibition of Myointimal Proliferation by Agiopeptin, a Somatostatin Analogue," JACC., 1991, 17(6), 132B-136B	
	64	Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," Circ. Res., 1987, 61, 296-300	
	65	Mak, K-H. et al., "Clinical trials to prevent restenosis after percutaneous coronary revascularization," Ann N Y Acad Sci., 1997 Apr 15, 811, 255-84; discussion 284-8. Review	
	66	Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412-417	
	67	Mintz, G. S. et al., "Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study," Circulation. 1996 Jul 1, 94(1), 35-43	
	68	Mintz, G. S. et al., "Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty," Am J Cardiol, 1996 Feb 15, 77(5), 427-430	
	69	Mintz, G. S. et al., "Intravascular Ultrasound Assessment of the Mechanisms and Predictors of Restenosis Following Coronary Angioplasty," J Invasive Cardiol., 1996 Jan, 8(1), 1-14	
	70	Mintz, G. S. et al., "Intravascular ultrasound findings after excimer laser coronary angioplasty," Cathet Cardiovasc Diagn. 1996 Feb, 37(2), 113-118	

EXAMINER

DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
	Confirmation No. 8413	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

71	Mintz, G. S. et al., "Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization," J Am Coll Cardiol, 1996 Jun, 27(7), 1678-1687
72	Mintz, G. S. et al., "Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis," Am J Cardiol. 1996 Aug 14, 78(3A), 18-22
73	Mintz, G. S. et al., "Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions," Circulation. 1996 Mar 1, 93(5), 924-931
74	<u>Modern Fluoropolymers</u> , (J. Scheirs, ed.), John Wiley & Sons, New York, 1997, pp. 77-87
75	Nemecek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor <i>in Vitro</i> and Neoinimal Proliferation <i>in Vivo</i> ," J. Pharmacol. Exp. Thera., 1989, 248, 1167-1174
76	Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," Neurosurgery, 1989, 25, 892-898
77	Popma, J. J. et al, "Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings," Am J Cardiol., 1991 Feb 15; 67(5), 431-433
78	Popma, J. J. et al., "Adjuncts to thrombolysis for myocardial reperfusion," Ann Intern Med., 1991 Jul 1, 115(1), 34-44
79	Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," Circulation, 1991 Sep, 84(3), 1426-1436
80	Popma, J. J. et al., "Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy," J Am Coll Cardiol., 1991 Nov 1, 18(5), 1183-1189
81	Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," Science, 1989, 245, 186-188
82	Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," N Engl J Med, 1994 Aug 25; 331(8), 489-495

EXAMINER**DATE CONSIDERED**



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-0929	Application No. 09/887,464
	Applicant Gerard H. Llanos, et al.	
	Filing Date June 22, 2001	Group 3743
	Confirmation No. 8413	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

83	Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circulation. 1993 Oct; 88(4 Pt 1), 1588-1601
84	Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," Circulation, 1996 Feb 1; 93(3), 412-422
85	Serruys, P. W. et al., "Randomized trials of coronary stenting," J Interv Cardiol, 1994 Aug; 7(4), 331
86	Serruys, P. W. et al., "Restenosis revisited: insights provided by quantitative coronary angiography," Am Heart J, 1993 Nov; 126(5), 1243-1267
87	Serruys, P. W. et al., "The bailout stent. Is a friend in need always a friend indeed?" Circulation, 1993 Nov; 88(5 Pt 1), 2455-2457
88	Seto, S. et al., "Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes," J Clin Invest, 1985 Feb, 75(2), 377-383
89	Simons, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> ," Nature, 1992, 359, 67-70
90	Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," Am. J. Pathol., 1990, 137, 313-330
91	Sollot, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," J. Clin. Invest., 1995, 95, 1869-1876
92	Tanaka, H. et al., "Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury," Circulation, 1993 Oct; 88(4 Pt 1), 1788-1803
93	Tardif, et al., "Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group," N Engl J Med. 1997 Aug 7; 337(6), 365-372
94	Teirstein, P. S. et al., "Catheter-based radiotherapy to inhibit restenosis after coronary stenting," N Engl J Med., 1997 Jun 12; 336(24), 1697-1703
95	Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," Int. J. Rad. Onc. Biol. Phys., 1996, 36, 767-775
96	Yokoi, H. et al., "Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial," J Am Coll Cardiol., 1997 Oct; 30(4), 855-862

EXAMINER

DATE CONSIDERED

<p align="center">SUBMISSION UNDER MPEP 609 D</p> <p align="center">Page 1 of 1</p>	<i>Application Number</i>	09/887,464
	<i>Filing Date</i>	June 22, 2001
	<i>First Named Inventor</i>	Gerard H. Llanos
	<i>Group Art Unit</i>	3743
	<i>Examiner Name</i>	Nguyen, Camtu Tran
	<i>Attorney Docket Number</i>	CRD-0929

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
			Office ³	Number ⁴	KindCode ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--